RaQualia Pharma Inc.
TSE:4579.T
562 (JPY) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) JPY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,901.202 | 2,918.038 | 2,776.233 | 1,107.301 | 1,702.973 | 744.517 | 1,419.195 | 705.235 | 145.5 | 153.895 | 228.044 | 28.978 | 684.202 | 1,186.759 |
| Cost of Revenue
| 420.617 | 231.586 | 320.674 | 138.012 | 262.804 | 89.411 | 149.534 | 117.63 | 53.353 | 2.552 | 0.307 | 0 | 11.429 | 101.734 |
| Gross Profit
| 1,480.585 | 2,686.452 | 2,455.559 | 969.289 | 1,440.169 | 655.106 | 1,269.661 | 587.605 | 92.147 | 151.343 | 227.737 | 28.978 | 672.773 | 1,085.025 |
| Gross Profit Ratio
| 0.779 | 0.921 | 0.884 | 0.875 | 0.846 | 0.88 | 0.895 | 0.833 | 0.633 | 0.983 | 0.999 | 1 | 0.983 | 0.914 |
| Reseach & Development Expenses
| 1,203.965 | 1,248.678 | 1,127.397 | 932.451 | 864.251 | 1,074.619 | 848.516 | 796.229 | 1,302.452 | 1,515.582 | 1,518.023 | 1,804.015 | 1,660.952 | 1,652.672 |
| General & Administrative Expenses
| 620.954 | 571.538 | 620.301 | 522.915 | 591.862 | 655.596 | 571.555 | 551.252 | 707.644 | 819.325 | 847.685 | 861.861 | 928.431 | 777.901 |
| Selling & Marketing Expenses
| -6.969 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 613.985 | 571.538 | 620.301 | 522.915 | 591.862 | 655.596 | 571.555 | 551.252 | 707.644 | 819.325 | 847.685 | 861.861 | 928.431 | 777.901 |
| Other Expenses
| 14.583 | -0.211 | -0.848 | 2.113 | 1.045 | 3.998 | 45.05 | 21.444 | 1.26 | 5.535 | 269.884 | -255.662 | 38.351 | 72.066 |
| Operating Expenses
| 1,817.95 | 1,820.216 | 1,747.698 | 1,455.366 | 1,456.113 | 1,730.215 | 1,420.071 | 1,347.481 | 2,010.096 | 2,334.907 | 2,365.708 | 2,665.876 | 2,589.383 | 2,430.573 |
| Operating Income
| -337.365 | 866.235 | 707.86 | -486.077 | -25.842 | -1,075.109 | -150.411 | -759.876 | -1,864.597 | -2,183.564 | -2,137.971 | -2,636.898 | -1,916.612 | -1,345.549 |
| Operating Income Ratio
| -0.177 | 0.297 | 0.255 | -0.439 | -0.015 | -1.444 | -0.106 | -1.077 | -12.815 | -14.189 | -9.375 | -90.997 | -2.801 | -1.134 |
| Total Other Income Expenses Net
| 43.316 | -15.224 | 172.719 | -41.864 | 53.153 | -3.084 | 90.562 | 37.171 | 16.136 | 1,551.865 | 1,035.813 | -264.725 | 10.181 | 49.709 |
| Income Before Tax
| -294.049 | 851.011 | 880.579 | -527.941 | 27.311 | -1,078.193 | -59.848 | -722.705 | -1,848.46 | -631.699 | -1,102.158 | -2,901.623 | -1,906.429 | -1,295.839 |
| Income Before Tax Ratio
| -0.155 | 0.292 | 0.317 | -0.477 | 0.016 | -1.448 | -0.042 | -1.025 | -12.704 | -4.105 | -4.833 | -100.132 | -2.786 | -1.092 |
| Income Tax Expense
| 29.612 | 127.62 | 124.79 | 79.044 | 21.968 | 26.355 | -1.725 | 5.411 | 5.893 | 7.224 | 6.111 | 3.84 | 9.84 | 11.84 |
| Net Income
| -323.662 | 723.39 | 755.788 | -606.985 | 5.343 | -1,104.548 | -58.122 | -728.117 | -1,854.353 | -638.924 | -1,108.27 | -2,905.463 | -1,916.269 | -1,307.679 |
| Net Income Ratio
| -0.17 | 0.248 | 0.272 | -0.548 | 0.003 | -1.484 | -0.041 | -1.032 | -12.745 | -4.152 | -4.86 | -100.264 | -2.801 | -1.102 |
| EPS
| -14.98 | 34.5 | 36.07 | -28.97 | 0.26 | -54.23 | -2.99 | -38.8 | -116.45 | -45.7 | -82.7 | -219 | -172.85 | -261,118.01 |
| EPS Diluted
| -14.98 | 34.47 | 36.04 | -28.97 | 0.26 | -54.23 | -2.99 | -38.8 | -116.45 | -45.7 | -82.7 | -219 | -172.85 | -261,118.01 |
| EBITDA
| -161.801 | 1,055.213 | 1,016.986 | -403.775 | 114.208 | -935.469 | -83.541 | -686.069 | -1,736.147 | -2,102.581 | -2,787.357 | -2,598.211 | -1,897.355 | -1,321.792 |
| EBITDA Ratio
| -0.085 | 0.362 | 0.366 | -0.365 | 0.067 | -1.256 | -0.059 | -0.973 | -11.932 | -13.662 | -12.223 | -89.662 | -2.773 | -1.114 |